Regenerative Biology for Healthier Lives
Joined May 2013
- Tweets 226
- Following 389
- Followers 1,365
- Likes 290
77 Photos and videos
The $BRTX team recently visited IPS Labs to learn more about the science and expertise behind successful formulation development. Thank you to the full IPS team for providing an in-depth look at their facility, technologies, and approach to innovation!
8
200
$BRTX's fully enrolled, randomized, double-blind, sham-controlled Phase 2 study in cLDD has completed treatment administration in 99 patients, continuing Phase 3 readiness activities following @US_FDA Type B meeting alignment.
Read the full press release: bit.ly/4dxJoMf
4
14
589
Francisco Silva brings over two decades of entrepreneurial and clinical-development experience in cell- and biologic-based therapeutics. He combines hands-on scientific expertise with commercial strategy to advance next-generation orthobiologics and cell therapies.
$BRTX
1
9
224
Skincare is getting smart. BioCosmeceuticals’ biologic-powered products mix cutting-edge science with real cosmetic results. Learn how exosome and growth factor-based formulations are changing the game.
Find out more: bit.ly/4sN69Rj
$BRTX
8
313
$BRTX's CEO, Lance Alstodt, recently spoke with @Xtalks about the evolving landscape of regenerative medicine and the promise and challenges of stem cell-based therapies in treating chronic conditions like degenerative disc disease.
Listen here: youtube.com/watch?v=n_Z89oBe…
1
12
751
The last patient has been dosed in $BRTX's fully enrolled Phase 2 clinical trial evaluating BRTX-100 for the treatment of cLDD, completing treatment administration of its lead clinical program & advancing the study into the next blinded follow-up stage.
🔗 bit.ly/4dxJoMf
2
13
542
Chronic lower back pain remains one of the most persistent and costly challenges in global healthcare.
$BRTX's President & CEO, Lance Alstodt, shares how our team is working to redefine spine care through autologous cell therapy in this byline article: drugdeliveryleader.com/doc/s…
2
15
405
Today is #ClinicalTrialsDay, a celebration and recognition of participants, researchers, and @US_FDA staff. $BRTX is proud of the progress being made across our ongoing clinical trials as we work to utilize regenerative biology for longevity and healthier lives.
@ACRPDC
11
343
$BRTX announces the presentation of new preclinical data at #ISCT26. The new data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications.
Read more: bit.ly/4354Hyt
@ISCTglobal
1
10
278
$BRTX recently announced expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100 at @ISCTglobal.
The blinded ISCT dataset showed sustained improvements in both pain and function among patients with CLDD.
🔗 ir.biorestorative.com/news-e…
2
10
394
$BRTX announces expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100, showing sustained improvements in both pain and function among patients with CLDD.
Learn more about the data presented at @ISCTglobal: bit.ly/4no20l6
#ISCT2026
1
3
20
512
Don’t miss $BRTX's presentations at @ISCTglobal! Our team will share the latest safety and blinded efficacy data from our fully enrolled, ongoing Phase 2 study in chronic lumbar disc disease and preclinical data on our therapeutic and biocosmeceutical exosome platform.
#ISCT2026
1
3
18
2,632
$BRTX announces that it will present new data at the @ISCTglobal 2026 Annual Meeting next week.
Learn more about both upcoming presentations here: bit.ly/48BK8wS
#ISCT26 #ISCT2026
3
13
452
$BRTX intends for Dr. David J. Goldberg to lead a prospective, controlled human clinical study designed to generate comparative outcome data evaluating improvements in skin appearance, texture, & quality relative to current aesthetic treatment benchmarks.
bit.ly/4mJ2YYF
1
11
281
$BRTX's CEO, Lance Alstodt, spoke with the BioPharma BoardRoom on the advancements in our scalable stem cell therapies. Lance also discusses our targeted clinical strategy, autologous cell platforms, and a dual-track model for therapeutics.
Read more: biopharmaboardroom.com/inter…
4
15
604
Check out the latest milestones from $BRTX in a letter to shareholders from CEO, Lance Alstodt. We’re rolling into 2026 with a convergence of clinical, regulatory, and commercial momentum behind each of our programs.
Read the letter: bit.ly/46D9x8m
1
3
12
615
$BRTX announces a strategic partnership with David J. Goldberg, MD, JD, internationally recognized as one of the foremost innovators in laser dermatology, regenerative aesthetics, and clinical research leadership.
Read our full press release here: bit.ly/4mJ2YYF
2
15
449
CEO Lance Alstodt walks @irat1onal through $BRTX's unique approach to regenerative medicine on the @ProgressPotent1 Podcast.
Listen to their full discussion here: bit.ly/41qEoCc
4
13
389
$BRTX's CEO, Lance Alstodt, shared progress on our lead cell therapy candidate, BRTX-100, the regulatory and manufacturing landscape for autologous therapies, and the potential for regenerative platforms to reshape treatment approaches.
Read more here: drug-dev.com/expert-content/…
5
12
2,550